quavonlimab (MK-1308)

News alerts, weekly reports and conference planners

Company:

Akesobio, Merck (MSD)

Drug class:

CTLA4 inhibitor

Related drugs:

PD-L1 expression	Lung Non-Small Cell Squamous Cancer	PD-L1 expression	Lung Non-Small Cell Squamous Cancer	pembrolizumab + MK-1308 Sensitive: C3 – Early Trials pembrolizumab + MK-1308 Sensitive : C3	pembrolizumab + MK-1308 Sensitive: C3 – Early Trials pembrolizumab + MK-1308 Sensitive : C3
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	pembrolizumab + MK-1308 Sensitive: C3 – Early Trials pembrolizumab + MK-1308 Sensitive : C3	pembrolizumab + MK-1308 Sensitive: C3 – Early Trials pembrolizumab + MK-1308 Sensitive : C3

Associations
(2)